Taxation 2 (RoI) 2025–2026 is the taxation textbook for students on the Chartered Accountants Ireland CA Proficiency 2 course.

ISBN:  9781917822015

Published:  04/09/2025

Format:  Paperback, 464 pages

Price: €52.00

Taxation 1 (RoI) 2025–2026 is the taxation textbook for students on Chartered Accountants Ireland-sponsored CA Proficiency 1 courses.

ISBN:  9781913975999

Published:  22/07/2025

Format:  Paperback, 464 pages

Price: €50.00

This unique Irish textbook by Christine Nangle is designed to inform students about the background to auditing and then lead them in detail through the practicalities of the auditing and assurance process.

ISBN: 9781913975258

Format: Paperback, 1008 pages

This unique Irish textbook covers the entire audit process undertaken by independent external auditors, culminating in their independent auditor’s report. It is designed to inform students about the background to auditing and then lead them in detail through the practicalities of the auditing and assurance process.

External Auditing and Assurance: An Irish Textbook illustrates the context of the external auditing process as it relates to an entity's financial statements. The audit process is treated as a continuous discussion directly related to the final outcome, i.e. the auditor’s report, and the financial statements to which it refers. The specific audit procedures for each cycle in a set of financial statements are explained in detail, with worked examples that replicate the audit working papers and other documentation to complement this applied approach.

For this 4th Edition the text has been extensively updated to reflect the most recent ethical and auditing standards as issued by the IAASA and the FRC (as at 1 January 2022), including the new standards on quality management. Developments in the auditor's regulatory environment in both Ireland and the UK are explained, as well as relevant changes in company law and corporate governance.This edition also considers the wider issues affecting auditing, such as the impact of geopolitical events, and their implications for auditors.

Some key features of this new edition also include:

• an extensively revised chapter on the application of data analytics, robotic process automation, artificial intelligence, blockchain and cloud computing and their impact on the audit;

• an increased focus on professional scepticism and professional judgement;

• a new chapter on non-audit engagements.

Contents

Introduction (including future developments in auditing and assurance)

Part I – The External Auditing and Assurance Environment

1. External Auditing and Assurance

2. Ethics and Corporate Governance

3. Fraud and Compliance with Laws & Regulations

Part II – The Audit and Assurance Process: Planning and Controls

1. The Audit Process

2. Audit Acceptance and Planning

3. Gathering Audit Evidence

4. The Risk Assessment Process

5. Controls and Control Testing

6. Computer-Assisted Audit Techniques and Other Technology Considerations

7. Using the Work of Others

Part III – The Audit and Assurance Process: Substantive Procedures

1. The Audit of Property, Plant and Equipment

2. The Audit of Inventory

3. The Audit of Revenue and Receivables

4. The Audit of Bank and Cash

5. The Audit of Investments

6. The Audit of Purchases and Payables

7. The Audit of Share Capital and Reserves

Part IV – The Audit and Assurance Process: Conclusion and Reporting

1. Audit Completion Procedures

2. Audit Reports

3. Group Audits

Part V – Non-Audit Engagements

21. Non-Audit Engagements

• Appendix A – Large Company Ltd – Directors’ Report and Financial Statements

• Appendix B – Suggested Solutions to Review Questions

• Glossary

This seminal textbook by Ciaran Connolly, a leading academic with an extensive background in accountancy practice, is designed to provide students with the knowledge and skills to appraise underlying accounting concepts and apply extant international accounting standards.

Designed to provide students with the knowledge and skills to appraise underlying accounting concepts and apply extant International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) this revised 6th edition has been fully updated to reflect the requirements of all IASs and IFRSs extant at 31 March 2023. It includes questions and extensive worked examples on these standards and, innovatively, highlights key differences between IASs/IFRSs and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland .

International Financial Accounting and Reporting is particularly suitable for the intermediate and advanced levels of undergraduate accounting degree programmes, together with postgraduate and professional courses.

Key features of the 6th Edition(Revised) include:

• consideration of the implications of FRS 102 (issued in January 2022);

• discussion of accounting and professional ethics (with related questions and solutions);

• the adoption of IFRS 15 Revenue from Contracts with Customersand IFRS 16 Leases;

• eight chapters that deal comprehensively and specifically with accounting for business combinations;

• separate chapters addressing issues such as the accounting treatment of financial instruments, employee benefits and share-based payments.

Format: Paperback, 1,112 pages
Published: July 2023

Designed to make consolidation more approachable for the student, this textbook by Paul Mahony & Niall MacLochlainn leads the reader step-by-step through the consolidation of financial statements, supported by numerous examples, comprehensive questions and fully worked solutions.

The preparation and presentation of consolidated financial statements is a large and complex area of study that forms an integral part of the financial accounting/corporate reporting syllabi of the accountancy bodies and most accounting, commerce and business studies degree programmes.

Written and designed to make consolidation more approachable for the student, this book leads the reader, using a step-by-step approach, through the consolidation of financial statements, supported by numerous examples, comprehensive questions and fully worked solutions including those from past professional accountancy examination papers.

This 3rd edition is updated to incorporate changes to relevant accounting standards since the 2nd edition (2013) and is up to date to 31 December 2016. This new edition also includes new chapters on:

• business combinations achieved in stages; and

• vertical/complex group holdings.

Key features of this textbook:

• Advice on how to approach examination questions on consolidation.

• Worked examples and solutions throughout the text.

• A large and comprehensive question bank, requiring the preparation and presentation of a consolidated:

  • Statement of Financial Position;

  • Statement of Profit or Loss and Other Comprehensive Income;

  • Statement of Changes in Equity involving a parent, a subsidiary and a joint venture.

• Solutions to all of the questions and a comprehensive set of journal entries dealing with the consolidation procedures and all the ‘complications’.

• Workings for questions and worked examples requiring the preparation of a consolidated statement of financial position are presented using both the more traditional T-account method as well as the columnar method now adopted by many lecturers and students.

ISBN: 9781910374771

Published: 18/07/2017

Format: Paperback, 386 pages

AUTHOR: Peter Clarke

ISBN: 9781910374672

FORMAT: Paperback

PUBLISHER: Chartered Accountants Ireland

PUB DATE: 31 August 2016

AUTHOR: David Cowan

ISBN: 9781526531001

FORMAT: Hardback

PUBLISHER: Bloomsbury Professional

PUB DATE: 19 September 2025

AUTHOR(S): Dr. Maebh Harding, Dr. Deirdre McGowan

ISBN: 9781911611875

FORMAT:Paperback

PUBLISHER: Clarus Press

PUBLISHING: 12 October 2023

AUTHOR: Laura Donnellan

ISBN: 9781911611196

FORMAT: Paperback

PUBLISHER: Clarus Press

PUB DATE: December 2024

AUTHOR: Dr. Lydia Bracken

ISBN: 9781917134187

FORMAT: Paperback

PUBLISHER: Clarus Press

PUB DATE: September 2025

ISBN: 9781975169527

The ideal introductory text for a rigorous approach to biomechanics, Biomechanical Basis of Movement, Fifth Edition helps build a precise, comprehensive grasp of the full continuum of human movement potential.

Focusing on the quantitative nature of biomechanics, this exacting but approachable text applies laws of motion and mechanics to in-depth analysis of specific movements, integrating current literature, meaningful numerical examples, relevant applications, hands-on exercises and functional anatomy, physics, calculus and physiology. Content is organized into sections that build upon each other to offer a structured introduction to biomechanics as it relates to exercise science. The extensively updated Fifth Edition emphasizes clinical relevance with integrated examples and questions and offers an expansive suite of digital resources, including new artwork, animations, and multiple eBook options to make mastery of biomechanics more accessible than ever.

• UPDATED! Content reflects the latest perspectives on functional anatomy and highlights the clinical relevance of biomechanics for successful Allied Health practice.

• UPDATED! Extensively revised illustrations clarify anatomical structures and movements in full color.

• NEW! Animations available within the VitalSource® eBook and on thePoint reinforce functional anatomy and mechanical motion concepts with vibrant detail.

• NEW! Problem calculators built into the VitalSource® eBook, provide essential practice using different formulas to answer questions.

• Chapter objectives, outlines, and summaries focus your attention on essential concepts and reinforce key takeaways.

• Review questions at the end of each chapter test your comprehension and challenge you to apply concepts in a clinical context.

Lippincott® Connect features:

• Lifetime access to the digital version of the book with the ability to highlight and take notes on key passages for a more personal, efficient study experience.

• Carefully curated resources, such as interactive diagrams, video tutorials, organ sounds, and self-assessment, all designed to facilitate further comprehension.

Lippincott® Connect also allows users to create Study Collections to further personalize the study experience. With Study Collections you can:

• Pool content from books across your entire library into self-created Study Collections based on discipline, procedure, organ, concept or other topics.

• Display related text passages, video clips and self-assessment questions from each book (if available) for efficient absorption of material.

• Annotate and highlight key content for easy access later.

• Navigate seamlessly between book chapters, sections, self-assessments, notes and highlights in a single view/page.

ISBN: 9781451193831

Setting the standard for more than 30 years, Exercise Physiology has helped more than 350,000 students build a solid foundation in the scientific principles underlying modern exercise physiology.

This Eighth Edition is updated with the latest research in the field to give you easy-to-understand, up-to-date coverage of how nutrition, energy transfer, and exercise training affect human performance.

A vibrant new full color "magazine style" design, along with updated art in every chapter, works hand in hand with the descriptive content, making even complex topics easier to understand and key information easier to locate.

Throughout the text, the authors apply exercise physiology principles to practical skills, illustrate how theory comes to life through research, and clarify complex issues and problems. References posted online provide the evidence behind the science, as well as a complete list for further reading.

• Get quick access to the resources available to help you master each section of the text with "Ancillaries at a Glance."

• Maximize your study time with the book's vibrant, "magazine style" design that makes the content more engaging and accessible and key information easier to find.

• Reinforce your understanding with Chapter Objectives, Integrative Questions that pose open-ended questions for reflection on complex concepts, and FYI sections that offer "good to know" information.

• Gain an understanding of how researchers contribute to our knowledge of exercise physiology through engaging section-opening interviews with key figures in the field.

• Learn how theoretical concepts relate to practical skills through "In a Practical Sense" features.

• Access the most relevant current information in the field through figures and tables that clarify important concepts and information.

• Gain an understanding of the past, present, and future of the profession through coverage of important milestones and future directions in the field.

• Visit the free companion website for anywhere, anytime access to over 30 animations of key exercise physiology concepts, the book's complete list of references, and more.

September 2025 edition

ISBN: 9780857114884

£79 Sterling RRP

Practical and evidence-based, BNF for Children (BNFC) is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.

Relied on by health professionals who prescribe, dispense, and administer medicines to paediatrics, BNFC supports confident decision-making at the point of care. including best practice guidelines and advice from a network of paediatric experts. The process is overseen by a paediatric formulary committee.

Extensive content updates in BNFC 2025-2026 edition include:

New monographs for:

• Agamree® [vamorolone] for treatment of Duchenne muscular dystrophy

• Apretude® [cabotegravir] for pre-exposure prophylaxis of HIV-1 infection

• Biktarvy® [bictegravir with emtricitabine and tenofovir alafenamide] for treatment of HIV1 infection

• Duvyzat® [givinostat] for treatment of Duchenne muscular dystrophy

• Emollient creams and ointments, hydrogenated castor-oil containing for treatment of dry skin conditions, eczema, and psoriasis

• Joenja® [leniolisib] for treatment of activated phosphoinositide 3-kinase delta syndrome

• Methenamine hippurate for prophylaxis of uncomplicated lower urinary-tract infection

• Ospolot® [sultiame] for treatment of rolandic epilepsy (self-limited epilepsy with centrotemporal spikes)

• Piasky® [crovalimab] for treatment of paroxysmal nocturnal haemoglobinuria

• Sogroya® [somapacitan] for treatment of deficiency of growth hormone

• Winlevi® [clascoterone] for treatment of acne vulgaris

MHRA advice on:

• Carbamazepine (Tegretol® 100mg/5mL liquid): temporary stock-out and update to posology (reduction of maximum daily dose)

• Dabigatran etexilate: Direct-acting oral anticoagulants (DOACs): paediatric formulations

• Epimax® ointment and Epimax® paraffin-free ointment: reports of ocular surface toxicity and ocular chemical injury

• GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation

• GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse

• Medroxyprogesterone acetate: risk of meningioma and measures to minimise this risk

• Montelukast: reminder of the risk of neuropsychiatric reactions

• Prolonged-release opioids: removal of indication for relief of post-operative pain

• Sodium valproate: new advice for male patients already taking sodium valproate and new precautionary advice for male patients

• Topical corticosteroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions

• Topiramate (Topamax®): introduction of new safety measures, including a Pregnancy Prevention Programme

• Valproic acid: new advice for male patients already taking valproic acid and new precautionary advice for male patients

• Warfarin sodium: to be alert to the risk of drug interactions with tramadol

Other significant changes include updated guidance on:

• Amphotericin B: review of indications and dose for liposomal preparations, as well as updates to directions for administration, breast-feeding, pregnancy, cautions, and monitoring advice

• Anaemia, iron deficiency: updated guidance for oral iron

• Antibacterials, principles of therapy: update to notifiable diseases reporting

• Antibacterials, use for prophylaxis: updated guidance on secondary prevention of meningococcal disease and secondary prevention of pertussis

• Asthma, chronic: updated guidance on management

• Budesonide with formoterol (DuoResp Spiromax® 160 micrograms/4.5 micrograms, and Fobumix® 160/4.5 Easyhaler): new indication and dose for mild asthma, reliever therapy.

• Cefotaxime: removal of indication and dose for emergency treatment of suspected bacterial meningitis or meningococcal disease, before urgent transfer to hospital, in patients who cannot be given benzylpenicillin

• Ceftriaxone: update to indications and dosing for pre-hospital treatment of suspected bacterial meningitis and meningococcal disease

• Central nervous system infections, antibacterial therapy: updated guidance on management

• Chloramphenicol: updated monitoring advice

• Cholera vaccines: updated guidance for immunisation

• Co-amoxiclav: update to structure of indications and dose section; tablet dose expression changed to co-amoxiclav (total of amoxicillin and clavulanic acid)

• Co-codamol: update to dose expression

• Combined hormonal contraceptives: update to breast-feeding advice

• Dalteparin sodium: update to indications and dosing for treatment and prophylaxis of thromboembolism, and associated monitoring requirements

• Dexamethasone: update to dose advice for adjunctive treatment of suspected bacterial meningitis

• Ear: updated guidance for the removal of ear wax

• Emtricitabine with tenofovir alafenamide: new indication and dose for pre-exposure prophylaxis of HIV-1 infection

• Fever: updated guidance on management

• Gonadotrophin-releasing hormone analogues: new restrictions on use for puberty suppression

• Human papillomavirus vaccine: updated guidance for immunisation

• Hydroxychloroquine sulfate: updated pregnancy and breast-feeding advice

• Immunisation schedule: updated guidance for immunisation against diphtheria, tetanus, pertussis and poliomyelitis in children aged 3 years and 4 months; immunisation against influenza; immunisation against pertussis in pregnancy

• Influenza vaccine: updated guidance for immunisation

• Intra-uterine contraceptive devices (copper): name change of Novaplus T 380® Ag to Eurogine T 380® Ag, and name change of Novaplus T 380® Cu to Eurogine T 380® Cu.

• Malaria, prophylaxis: updated guidance

• Medical emergencies in the community: update to antibacterials for suspected bacterial meningitis and meningococcal disease; update to guidance on the use of salbutamol in the management of acute asthma

• Neonatal infection, antibacterial therapy: updated guidance on management

• Nutritional Borderline Substances re-arranged to align with changes made to the categorisation and coding of these products by the Advisory Committee on Borderline Substances and NHS Business Services Authority

• Oral iron: indications and doses updated for iron-deficiency anaemia (advice in ferrous sulfate, ferrous fumarate, ferrous gluconate, sodium feredetate)

• Parenteral anticoagulants: updated guidance for use of heparin flushes

• Pertussis vaccine: updated guidance for immunisation

• Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change of Apexxnar® to Prevenar 20®

• Poisoning, emergency treatment: updated guidance for paracetamol overdose

• Respiratory system infections, antibacterial therapy: updated guidance on fluoroquinolones

• Sacubitril with valsartan: update to dose expression

• Sepsis: updated guidance on management

• Status epilepticus: updated guidance for management

• Sympathomimetics: updated guidance for septic shock

• Tuberculosis: updated guidance for multi-drug resistant tuberculosis

• Urinary-tract infections: updated guidance on fluoroquinolones, prophylaxis of recurrent urinary tract infections, and treatment of lower urinary-tract infections

BNFC is published jointly by BMJ Group, Pharmaceutical Press, RCPCH, and NPPG.

ISBN 9780853696025

Pharmaceutical Calculations Workbook is the companion self-study aid to Introduction to Pharmaceutical Calculations . It contains practice calculations (with answers) similar to those encountered in pharmacy exams and in practice.

Each chapter contains a variety of exercises for practising calculations using the methods covered in the companion text. Tables for completion are included in addition to individual drug- or patient-specific questions.

This workbook will be invaluable to pharmacy students and preregistration pharmacists, as well as others who want to practise basic pharmaceutical calculations.

Rees, Judith A; Smith, Ian; Watson, Jennie

ISBN 9780857111685

Introduction to Pharmaceutical Calculations is your comprehensive guide to successfully performing pharmaceutical calculations. Now in its fourth edition, this popular book covers everything you need to know to pass those all important pharmacy calculation exams.

Every chapter contains learning objectives, worked examples and sample questions and has been fully updated.

Brand new features include:

• Introduction (including expert tips for approaching calculations)

• Doses in children

• 8 short videos (to help you grasp some of the key concepts) covering:

  • Simple dilution

  • Proportional sets

  • Conversion of units

  • Representations of concentrations

  • Mixing two concentrations without a final volume

  • Displacement values

  • Parenteral doses

  • Moles

ISBN: 9780857114938

Published: 7th Aug, 2025

RRP: £70 Stg

Type: Paperback

Dimensions: 234x156mm

Page count: 600

Dale and Appelbe’s Pharmacy and Medicines Law covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in Great Britain.

This edition has been extensively revised to include:

• New chapters on Hospital pharmacy and Online pharmacy

• Expanded coverage of manufacturing and clinical trials

• Addition of new case law to many of the chapters

• Topical issues are covered and illustrated by action taken by regulators

Changes in the law since the 12th edition, including:

• Regulations governing veterinary medicines.

• Many changes resulting from Brexit, and the Windsor Framework which came into force on 1 January 2025.

• New legal duties of superintendent pharmacists and responsible pharmacists.

• Chief pharmacists.

• Original pack dispensing.

• New case law on pharmacist supervision.

• Medical examiners.

From Foreword in the new edition  "Pharmacy has an honourable tradition as keeper of the health professions' body of knowledge and professional conscience when it comes to medicines and the complex laws governing their safe and effective use. This new, 13th edition of Dale and Appelbe's Pharmacy and Medicines Law provides essential underpinning for this unique and enduring aspect of the pharmacy professions' vocation”

Duncan Rudkin, CEO, General Pharmaceutical Council, April 2025

ISBN: 9780857114952

£70 Sterling RRP

Published July 2025

Medicines, Ethics and Practice is the Royal Pharmaceutical Society’s established professional guide for pharmacists. Updated and revised annually, it is a practical resource which helps pharmacists practice confidently and professionally.

It embeds professionalism at the heart of decision-making processes and provides essential information, supporting the pharmacist in their day-to-day practice.

September 2025 edition

ISBN: 9780857114907

£79 Sterling RRP

The first choice for concise medicines information

Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.

Practical and evidence-based, BNF is an integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally.  Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care.

Extensive content updates in the BNF 90 edition include:

New monographs for:

• Agamree® [vamorolone] for treatment of Duchenne muscular dystrophy

• Anzupgo® [delgocitinib] for treatment of moderate-to-severe hand eczema

• Briumvi® [ublituximab] for treatment of multiple sclerosis

• Duvyzat® [givinostat] for treatment of Duchenne muscular dystrophy

• Joenja® [leniolisib] for treatment of activated phosphoinositide 3-kinase delta syndrome

• Kisunla® [donanemab] for treatment of mild cognitive impairment or mild dementia in Alzheimer’s disease

• Lunivia® [eszopiclone] for short-term treatment of insomnia

• Vafseo® [vadadustat] for treatment of symptomatic anaemia associated with chronic kidney disease in patients on chronic maintenance dialysis

• Winlevi® [clascoterone] for treatment of acne vulgaris

• Yorvipath® [palopegteriparatide] for treatment of chronic hypoparathyroidism

MHRA advice on:

• Fezolinetant: risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment

• GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation

• Prolonged-release opioids: removal of indication for relief of post-operative pain

• Sodium valproate and Valproic acid: new advice for male patients already taking these

Other significant changes include updated guidance on:

• Amphotericin B: review of indications and dose for liposomal preparations, as well as updates to directions for administration, breast-feeding, pregnancy, cautions, and monitoring advice

• Apixaban: update to structure of dosing for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor

• Asthma, chronic: updated guidance on management

• Bempedoic acid: new indication and dose for established or at high-risk of atherosclerotic cardiovascular disease

• Bimekizumab: new indication and dose for hidradenitis suppurativa

• Budesonide with formoterol (DuoResp Spiromax® 160 micrograms/4.5 micrograms, and Fobumix® 160/4.5 Easyhaler): new indication and dose for mild asthma, reliever therapy

• Cardiovascular disease risk assessment and prevention: updated guidance

• Chloroquine: updated pregnancy and breast-feeding advice when used for rheumatic disease

• Contraceptives, hormonal: inclusion of guidance for use of combined oral contraceptives for preventive treatment of ovarian cancer in at-risk females

• Dupilumab: new indication and dose for chronic obstructive pulmonary disease

• Emtricitabine with tenofovir alafenamide: new indication and dose for pre-exposure prophylaxis of HIV-1 infection

• Hydroxychloroquine sulfate: updated pregnancy and breast-feeding advice

• Malaria prophylaxis: updated guidance

• Naltrexone hydrochloride: new indication and dose for gambling-related harm

• Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change of Apexxnar® to Prevenar 20®

• Sepsis: updated guidance on management

• Smoking cessation: updated drug treatment guidance

• Sympathomimetics: updated guidance for septic shock

• Tuberculosis: updated guidance for multi-drug resistant tuberculosis

• Wegovy® (semaglutide): new indication and dose for cardiovascular risk reduction

BNF is published jointly by BMJ Group and Pharmaceutical Press.